This CPB has been revised to state the following: (i) suprachoroidal injection (i.e., triamcinolone acetonide injectable suspension [Xipere]) is considered medically necessary for the treatment of macular edema associated with uveitis when criteria are met in the corresponding CPB for Triamcinolone Acetonide Injectable Suspension (Xipere), and (ii) suprachoroidal injection of all other pharmacologic agents is considered experimental and investigational for all indications because the effectiveness of this approach has not been established.